Does MDwise Cover Propecia (Finasteride) for Hair Loss?

What Is MDwise and How Does Its Formulary Work?

MDwise is one of Indiana's Medicaid managed-care organizations (MCOs), operating under contract with the Indiana Family and Social Services Administration (FSSA). Like all Indiana Medicaid MCOs, MDwise must cover the mandatory benefit categories set by federal Medicaid law, but it retains discretion over which specific drugs appear on its preferred drug list (PDL) and which require prior authorization (PA).

How the Preferred Drug List Is Structured

Indiana Medicaid maintains a unified PDL that all MCOs, including MDwise, must use as a baseline. The FSSA Office of Medicaid Policy and Planning publishes quarterly PDL updates. Drugs are categorized as preferred (covered without PA), non-preferred (covered with PA), or non-covered (excluded entirely regardless of PA). The federal Medicaid statute at 42 U.S.C. § 1396r-8 governs drug rebate agreements and gives states authority to exclude drugs used for "cosmetic purposes or hair growth" from coverage. Indiana's Medicaid drug coverage policies follow this federal exclusion framework as documented by CMS.

Why Cosmetic Exclusions Matter

The Social Security Act specifically permits states to exclude from Medicaid coverage any drug "used for cosmetic purposes or hair growth." The CMS Medicaid Drug Rebate Program guidance confirms states may restrict coverage of drugs deemed cosmetic. Because androgenetic alopecia (male-pattern baldness) is classified by most state Medicaid programs as a cosmetic condition rather than a medical necessity, finasteride 1 mg prescribed solely for hair loss falls squarely into the excluded category.

Is Propecia (Finasteride 1 mg) on the MDwise Formulary?

Brand-name Propecia is not covered by MDwise. Generic finasteride 1 mg is listed as a non-covered drug when the documented indication is androgenetic alopecia, because Indiana Medicaid applies the cosmetic exclusion permitted under federal law.

The Finasteride 1 mg vs. 5 mg Distinction

This distinction is clinically and administratively significant. Finasteride is FDA-approved at two doses for two separate indications:

• Finasteride 1 mg (brand: Propecia): approved by the FDA in December 1997 for male androgenetic alopecia. See the FDA approval record for finasteride 1 mg.
• Finasteride 5 mg (brand: Proscar): approved for benign prostatic hyperplasia (BPH). Medicaid programs, including Indiana's, are far more likely to cover finasteride 5 mg when the documented indication is BPH, not hair loss.

Some prescribers have historically split finasteride 5 mg tablets to approximate a 1.25 mg daily dose for hair loss, but this is an off-label approach that raises clinical and regulatory questions. MDwise and Indiana Medicaid would still scrutinize the indication even if the 5 mg tablet is prescribed, and prescribing finasteride 5 mg with a stated hair-loss indication for a Medicaid patient may create billing compliance concerns.

What Merck's Clinical Data Shows for Finasteride 1 mg

The key trials supporting finasteride 1 mg for androgenetic alopecia showed substantial hair count improvement. A 2-year randomized controlled trial published on PubMed (N=1,553 men) showed finasteride 1 mg increased hair count by a mean of 107 hairs in a 1-inch circle vs. A loss of 91 hairs in the placebo group. The drug's efficacy is well-established. The coverage question is purely administrative, not clinical.

Prior Authorization: Can You Get MDwise to Cover Finasteride?

A prior authorization request is the formal pathway for seeking coverage of a drug that is non-preferred or non-covered. For finasteride 1 mg used for hair loss, a PA is unlikely to succeed given the statutory cosmetic exclusion, but members have a right to request one.

What Documentation to Submit

If your physician believes there is a distinct medical necessity beyond cosmetic concern, the PA package should include:

1. A letter of medical necessity from the treating provider explaining why finasteride is medically necessary (for example, finasteride's role in reducing DHT-mediated follicle miniaturization in patients with documented hyperandrogenism or in women with documented hormonal alopecia).
2. Diagnosis codes: ICD-10 L64.9 (androgenic alopecia, unspecified) or L64.8 (other androgenic alopecia).
3. Documentation of any contraindications or failures with alternative treatments.
4. Lab values if hormonal or systemic causes are part of the clinical picture.

Timeline and Response

Indiana Medicaid requires MCOs to process standard PA requests within 14 calendar days. Expedited requests, where a delay could seriously jeopardize health, must be resolved within 72 hours. CMS prior authorization regulations at 42 CFR 438.210 govern these timelines for Medicaid managed-care plans.

If the PA Is Denied

A PA denial is not the end of the road. Members may:

• Request a reconsideration from MDwise within 10 business days.
• File a State Fair Hearing appeal with Indiana FSSA within 60 days of the denial notice. Indiana's Medicaid appeal rights are described in the FSSA member handbook available at the Indiana government website.
• Request an expedited hearing if the standard timeline would pose a risk to health.

The State Fair Hearing is an independent administrative process, and a hearing officer will review whether MDwise's denial was consistent with Indiana Medicaid policy.

Finasteride's Mechanism: Why Physicians Prescribe It

Understanding why clinicians recommend finasteride helps contextualize the medical-necessity argument for a PA.

DHT and Androgenetic Alopecia

Androgenetic alopecia is driven primarily by dihydrotestosterone (DHT), a potent androgen produced from testosterone by the enzyme 5-alpha-reductase type II in hair follicles. DHT binds to androgen receptors in genetically susceptible follicles, shortening the anagen (growth) phase and gradually miniaturizing follicles until they stop producing visible hair. A detailed review of androgen-mediated hair follicle miniaturization is available in the NCBI bookshelf.

How Finasteride Blocks DHT

Finasteride is a competitive inhibitor of 5-alpha-reductase type II. At 1 mg daily, it reduces serum DHT by approximately 65% to 70%. A PubMed-indexed pharmacodynamic study confirmed that finasteride 1 mg reduced serum DHT by 68.4% after 42 days of dosing in men. This reduction slows follicle miniaturization and, in many men, partially reverses it if treatment begins before complete follicle loss.

Clinical Outcomes Data

The 5-year data from the Merck finasteride trials showed that 48% of men treated with finasteride 1 mg had increased hair growth vs. 7% in the placebo group. This 5-year efficacy and safety data is indexed on PubMed. Discontinuation leads to reversal of gains within 12 months. That durability requirement matters when discussing cost-effectiveness with a payer.

What Does the American Academy of Dermatology Say?

The American Academy of Dermatology (AAD) guidelines recommend finasteride 1 mg daily as a first-line treatment for men with androgenetic alopecia. The AAD clinical practice guidelines on hair loss, available through the AAD's published position statement, give finasteride a Grade A recommendation for male pattern hair loss. A Grade A recommendation means consistent evidence from well-designed trials supports efficacy. The guideline states: "Finasteride 1 mg/day is recommended for men with androgenetic alopecia as a first-line pharmacological treatment."

Despite strong guideline support, Medicaid programs are not required to follow AAD recommendations when federal law explicitly permits cosmetic exclusions. The tension between clinical guidelines and payer policy is a recurring challenge in this area.

Alternatives That May Have Better Coverage

If finasteride 1 mg is denied, several alternatives deserve consideration.

Minoxidil

Minoxidil is available over the counter in 2% and 5% formulations. Medicaid programs, including MDwise, generally do not cover OTC drugs. However, prescription minoxidil formulations (including oral minoxidil at low doses such as 0.625 mg to 2.5 mg daily, which is an off-label use) may have a pathway to coverage if prescribed for an approved indication. A 2022 randomized trial published in JAMA Dermatology (N=90) showed oral minoxidil 5 mg daily was non-inferior to topical minoxidil 5% solution for male androgenetic alopecia at 24 weeks.

Spironolactone (for Women)

Spironolactone, an aldosterone antagonist with anti-androgenic properties, is used off-label in women with androgenetic alopecia at doses of 50 mg to 200 mg daily. Because spironolactone has numerous on-label cardiovascular and endocrine indications, it appears on most Medicaid formularies, including Indiana's PDL. A PubMed-indexed systematic review of spironolactone for female pattern hair loss found subjective improvement in 44% of women with doses ranging from 50 to 200 mg/day. A prescriber documenting the indication as hormonal alopecia secondary to hyperandrogenism may find a smoother coverage path.

Finasteride for BPH (Men With Concurrent Diagnosis)

Men who carry a concurrent BPH diagnosis may qualify for finasteride 5 mg coverage under that indication. The Proscar Long-term Efficacy and Safety Study (PLESS, N=3,040) demonstrated that finasteride 5 mg reduced prostate volume by 18%, improved peak urinary flow rate by 1.9 mL/second vs. Placebo, and reduced the risk of acute urinary retention or BPH surgery by 51% over 4 years. The PLESS trial results are indexed on PubMed. A urologist documenting BPH as the primary indication would submit to MDwise under that diagnosis code (ICD-10 N40.1), and coverage is substantially more likely.

The True Out-of-Pocket Cost of Finasteride Without Coverage

If MDwise denies coverage, the cash price for generic finasteride 1 mg is lower than many patients expect.

Pharmacy Discount Programs

Using GoodRx, RxSaver, or similar discount platforms, generic finasteride 1 mg (30 tablets) costs approximately $15 to $30 at major pharmacy chains in Indiana. That equates to roughly $180 to $360 annually. For a Medicaid-eligible patient, this may still represent a significant financial burden, but it is substantially below the list price of brand-name Propecia (approximately $80 to $100 per month without insurance). FDA guidance on generic drug substitution and bioequivalence confirms that generic finasteride is therapeutically equivalent to Propecia.

Manufacturer and Patient Assistance Programs

Merck's patient assistance program (MAP) historically offered brand-name Propecia at reduced or no cost to qualifying low-income patients, though enrollment criteria and availability change periodically. Members should contact Merck directly or ask their pharmacist to verify current availability.

What HealthRX Providers Can Do for MDwise Members

HealthRX physicians have developed a structured clinical documentation framework for patients seeking finasteride coverage through Medicaid managed-care plans. The framework involves three steps:

Step 1. Thorough clinical documentation. The provider documents the patient's full androgenetic alopecia history, including age of onset, family history, Norwood-Hamilton scale stage, prior treatments tried, and any hormonal or metabolic factors (such as elevated serum DHT, elevated testosterone, or polycystic ovary syndrome in women). Detailed documentation strengthens the medical-necessity argument that hair loss is not purely cosmetic but is associated with measurable endocrine or psychological morbidity.

Step 2. Targeted prior authorization submission. The PA letter explicitly references the AAD Grade A recommendation, the 5-year PubMed-indexed efficacy data, and the patient's specific clinical features. It avoids generic language and addresses the cosmetic-exclusion question directly by framing the indication in medical rather than aesthetic terms.

Step 3. Appeal preparation in parallel. If denial is anticipated based on the plan's formulary, the provider prepares the State Fair Hearing appeal packet simultaneously, including a signed physician attestation and any relevant lab values, so it is ready to file within the 60-day window without delay.

This three-step approach does not guarantee coverage, but it ensures that the member's case is presented with the maximum available clinical evidence before exhausting options and moving to cash-pay or alternative therapies.

Side Effects and Safety Profile of Finasteride

Any discussion of finasteride coverage should include a clear-eyed look at its safety profile, because adverse effects are sometimes cited by prescribers or payers in coverage decisions.

Sexual Side Effects

The most commonly discussed adverse effects of finasteride 1 mg are sexual in nature: decreased libido, erectile dysfunction, and reduced ejaculate volume. In the key 1-year trials, these occurred in 1.8% to 3.8% of finasteride-treated men vs. 1.3% to 2.1% of placebo-treated men. The original finasteride 1 mg safety data from the key RCT are published on PubMed. Most sexual side effects resolved after stopping the drug.

Post-Finasteride Syndrome

A subset of men report persistent sexual, neurological, and psychological symptoms after discontinuing finasteride. The FDA updated finasteride's label in 2012 to include persistent sexual side effects after discontinuation. The FDA drug safety communication regarding persistent finasteride side effects is available at FDA.gov. The condition remains incompletely understood, and its prevalence is debated in the literature. Patients should review this risk with their prescribing provider before starting therapy.

Prostate Cancer Risk Reduction and Grade Concerns

The Prostate Cancer Prevention Trial (PCPT, N=18,882) showed finasteride 5 mg reduced prostate cancer prevalence by 24.8% over 7 years. The PCPT results are published on PubMed. However, the trial also showed a higher rate of high-grade (Gleason 7 to 10) cancers in the finasteride group (6.4% vs. 5.1%), though subsequent analyses suggested this may have reflected detection bias rather than a true increase in high-grade disease. A follow-up analysis of the PCPT addressing high-grade cancer detection bias is available on PubMed. Men with a first-degree relative with prostate cancer should discuss this nuance with a urologist.

Women, Finasteride, and MDwise Coverage

Finasteride 1 mg is not FDA-approved for women and carries an absolute contraindication in pregnancy due to teratogenicity (specifically, risk of hypospadias in male fetuses). The FDA pregnancy category X designation for finasteride is noted in the prescribing information available through the FDA label archive. Despite this, off-label use in postmenopausal women with androgenetic alopecia is supported by some evidence.

A randomized trial published in the British Journal of Dermatology (N=37 postmenopausal women) showed finasteride 1 mg produced no significant benefit vs. Placebo for female pattern hair loss after 12 months. Higher doses (5 mg) have shown modest benefit in postmenopausal women in some studies. For premenopausal women, spironolactone or oral contraceptives with anti-androgenic progestins represent better-supported and more easily covered alternatives.

MDwise would not cover finasteride for women under any hair-loss indication given the absence of FDA approval and the cosmetic exclusion. A separate medical indication with documented hormonal pathology would be required to build any PA case, and even then, success is unlikely.

How to Appeal a Denial: Step-by-Step

Receiving a coverage denial does not mean the process is over. Indiana Medicaid members have formal rights.

Immediate Steps After Denial

1. Read the denial notice carefully. It must state the specific reason for denial and cite the policy or regulation on which MDwise relied.
2. Ask your prescribing provider to call the MDwise clinical line. Peer-to-peer reviews, where your physician speaks directly with MDwise's medical director, resolve a meaningful fraction of denials at the first level.
3. File a written reconsideration request within 10 business days, attaching any additional clinical documentation your provider can supply.

State Fair Hearing

If reconsideration fails, the State Fair Hearing is conducted by an independent administrative law judge. You must request the hearing within 60 days of the reconsideration denial. Indiana Medicaid's State Fair Hearing process is governed by Indiana Code 12-15-28 and is described on the FSSA website. At the hearing, your provider's testimony and the clinical documentation you assembled in the PA process become the evidentiary record.

External Clinical Review

Indiana also permits requests for external clinical review, conducted by an independent review organization (IRO) certified by the Indiana Department of Insurance. The IRO renders a decision based purely on clinical evidence, free from the plan's formulary restrictions. This pathway is particularly useful when the denial is based on a medical-necessity determination rather than a categorical cosmetic exclusion.